


Product Details

Product name:	Anti-TNF-alpha & HSA (Ozoralizumab Biosimilar)	SKU:	BIO0994SM
Target Name:	TNF-alpha & HSA	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P01375 & P02768	Concentration:	Lyophilized
Clone#:	Ozoralizumab (Bispecific)	Isotype:	VHH-VHH-VHH
Reactivity:	Human	Calculated M.W.:	38.44 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-TNF-alpha & HSA Reference Antibody (Ozoralizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




Anti-TNF-alpha & HSA Reference Antibody (Ozoralizumab) is 96.3%, determined by SEC-HPLC.

ELISA



Ozoralizumab bound to TNFSF2/TNF-alpha protein, and then rebounded to secondary antibodies(Anti-Cameild-VHH1+VHH2-HRP), and read OD450. As shown in fig, Ozoralizumab bound human TNFSF2/TNF-alpha Protein-Fc, and the EC₅₀ was 0.02958 nM.

ELISA



Ozoralizumab bound to HSA protein, and then rebounded to secondary antibodies(Anti-Cameild-VHH1+VHH2-HRP), and read OD450. As shown in fig, Ozoralizumab bound human HSA Protein-Fc, and the EC₅₀ was 0.04855 nM.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.